Pharmaceutical Development Campus in Hull, UK, Available for Acquisition
A fully equipped pharmaceutical CMC development facility in Priory Park, Hull, is being offered for sale as part of Indivior PLC’s restructuring of its global operations. The site offers over 5,000 square meters on 2.51 hectares of owned land, representing a rare opportunity to acquire a licensed, operational development campus with room for significant expansion.
Highlights of the Hull facility include:
• cGMP drug product development pilot plant operating under an MHRA MIA IMP license.
• Home Office controlled drug authorization up to Schedule II.
• Competence in oral solid dosage and sublingual film formulations.
• Non-cGMP formulation, chemical development, and analytical development laboratories.
• cGMP analytical capabilities, including stability storage and method development.
• ANDA/NDA filing support.
• Diagnostic services for commercial drug substances and drug products.
• Equipment-rich operation with room for significant expansion.
Experienced management and technical staff may transfer with the operation, and Indivior has indicated that transitional service agreements may be available to the right buyer. The site’s proximity to several local universities provides an ongoing pipeline of scientific talent.
PharmaBioSource (PharmaBioSource.com), a pharmaceutical facility advisory firm, has been exclusively retained to manage the transaction. Interested parties should contact Kenneth Stokholm directly at [email protected].
Contact:
Kenneth Stokholm
PharmaBioSource
Mobile: +45 2524 2022
www.pharmabiosource.com